Publications by authors named "Frank Perabo"

Claim this Profile
P
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.
Apostolia M Tsimberidou, Farshid Dayyani, David Sommerhalder, Andrae L Vandross, Meredith S Pelster, Frank Perabo

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.
Arun A Azad, Howard Gurney, Craig Underhill, Lisa Horvath, Mark Voskoboynik, Frank Perabo

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
Chandtip Chandhasin, Van Dang, Frank Perabo, Joselyn Del Rosario, Young K Chen

Anticancer Drugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Corinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, Robert B Montgomery, Michael S Gordon, Frank Perabo

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
Emmanuel S Antonarakis, Chandtip Chandhasin, Erica Osbourne, Jun Luo, Marianne D Sadar, Frank Perabo

Oncologist· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Christopher P Evans, Celestia S Higano, Thomas Keane, Gerald Andriole, Fred Saad, Frank Perabo

Eur Urol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Frank Perabo

Eur Urol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Anthony M Joshua, Neal D Shore, Fred Saad, Kim N Chi, Carl A Olsson, Frank Perabo

Prostate· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Yohann Loriot, Kurt Miller, Cora N Sternberg, Karim Fizazi, Johann S De Bono, Frank G Perabo

Lancet Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Frank Perabo

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Frank Perabo

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells.
Frank G E Perabo, Gregor Landwehrs, Christian Frössler, Doris H Schmidt, S C Mueller

Urol Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
Jörg Ellinger, Peter Albers, Frank G Perabo, Stefan C Müller, Alexander von Ruecker

J Urol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
Jörg Ellinger, Volker Wittkamp, Peter Albers, Frank G E Perabo, Stefan C Mueller

J Urol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity.
Jörg Ellinger, Patrick J Bastian, Nadja Ellinger, Philip Kahl, Frank G Perabo

Cancer Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
Jörg Ellinger, Nadja El Kassem, Lukas C Heukamp, Swapna Matthews, Figen Cubukluoz, Frank G Perabo

J Urol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data.
Eva C Von Löw, Frank G E Perabo, Roswitha Siener, Stefan C Müller

In Vivo· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.
Frank G E Perabo, Christian Frössler, Gregor Landwehrs, Doris H Schmidt, Alexander von Rücker

Anticancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Andreas Wirger, Frank G E Perabo, Susanne Burgemeister, Ludwig Haase, Doris H Schmidt

Anticancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma.
Frank G E Perabo, Patricia L Willert, Andreas Wirger, Doris H Schmidt, Alexander Von Ruecker

Anticancer Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New agents in intravesical chemotherapy of superficial bladder cancer.
Frank G E Perabo, Stefan C Müller

Scand J Urol Nephrol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer.
Frank G E Perabo, Patricia L Willert, Andreas Wirger, Doris H Schmidt, Eva Wardelmann

Int J Cancer· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
Frank G E Perabo, André W Demant, Andreas Wirger, Doris H Schmidt, Mario Sitia

Anticancer Res· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2.
Frank G E Perabo, Andreas Wirger, Stefan Kamp, Heike Lindner, Doris H Schmidt

Anticancer Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and new strategies in immunotherapy for superficial bladder cancer.
Frank G E Perabo, Stefan C Müller

Urology· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis